Bristol-Myers Squibb Reports Robust Q3 2025, Raises Revenue Outlook
Highlights
- Total company sales: $12.2 billion
- Growth portfolio sales increased 17%
- Oncology portfolio: Opdivo sales up 6% to $2.5 billion
- Hematology: Reblozyl sales were $615 million, reflecting a 31% increase
- Breyanzi sales: $359 million, up 58%
- Cardiovascular: Camzyos sales grew 88% to $296 million
- Eliquis sales: $3.7 billion, up 23%
- Generated $6.3 billion in cash flow from operations
- Diluted earnings per share: $1.63
- Increasing full year revenue guidance to $47.5 - $48 billion
The third quarter of 2025 saw Bristol-Myers Squibb delivering impressive financial results, buoyed by the strong performance of its growth portfolio, strategic business development initiatives, and rigorous cost management.
Growth Portfolio Achievements
Bristol-Myers Squibb's growth portfolio remains a powerhouse, with a 17% year-over-year increase in sales. This robust performance is largely driven by a lineup of high-demand products including the oncology champion, Opdivo, which secured a 6% increase in global sales to $2.5 billion. Moreover, the company's hematology division thrived with Reblozyl achieving a 31% sales growth, totaling $615 million for the quarter.
Continuing this momentum, Breyanzi, the cell therapy asset, has seen its sales surge by 58%, reaching $359 million, and is now annualizing over $1 billion.
Cardiovascular and Hematology Triumphs
Camzyos led the impressive gains in the cardiovascular space, posting an 88% rise in sales, reaching $296 million. Eliquis, another cornerstone in the cardiovascular lineup, showcased a remarkable 23% growth, equivalent to $3.7 billion in sales, further supported by the anticipated favorable impact of Medicare Part D redesign.
Hematology assets also posted strong results with Breyanzi continuing its strong upward trend and expanding in large B-cell lymphoma markets.
Financial Health and Strategic Outlook
Bristol-Myers Squibb increased its full-year revenue guidance to a range between $47.5 billion and $48 billion. Operational leanness was reflected in the significant cash flow generation of $6.3 billion during the quarter. Earnings per share landed at $1.63, highlighting solid financial management amid net charges linked to acquired in-process R&D and licensing activities.
The company remains committed to strategic growth avenues, reinforcing its position through tactical acquisitions and partnerships, such as with BioNTech, which bolsters its competitive stance in the oncology sector.
In summary, Bristol-Myers Squibb's Q3 results underpin a strategic trajectory of growth and innovation, indicating a solid foundation for navigating the evolving landscape of the pharmaceutical industry.